Logo image of SOLY

Soliton Inc (SOLY) Stock Fundamental Analysis

NASDAQ:SOLY - Nasdaq - Common Stock

22.58  +0.03 (+0.13%)

After market: 22.59 +0.01 (+0.04%)

Fundamental Rating

2

SOLY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. SOLY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SOLY does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SOLY had negative earnings in the past year.
SOLY Yearly Net Income VS EBIT VS OCF VS FCFSOLY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 -5M -10M

1.2 Ratios

Industry RankSector Rank
ROA -69.93%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SOLY Yearly ROA, ROE, ROICSOLY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 0 -500 -1K -1.5K

1.3 Margins

SOLY does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -4832.43%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SOLY Yearly Profit, Operating, Gross MarginsSOLY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, SOLY has more shares outstanding
SOLY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SOLY Yearly Shares OutstandingSOLY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 5M 10M 15M 20M
SOLY Yearly Total Debt VS Total AssetsSOLY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 10M 20M 30M

2.2 Solvency

SOLY has an Altman-Z score of 63.35. This indicates that SOLY is financially healthy and has little risk of bankruptcy at the moment.
There is no outstanding debt for SOLY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 63.35
ROIC/WACCN/A
WACCN/A
SOLY Yearly LT Debt VS Equity VS FCFSOLY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 10M -10M 20M 30M

2.3 Liquidity

SOLY has a Current Ratio of 5.47. This indicates that SOLY is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 5.37 indicates that SOLY has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 5.47
Quick Ratio 5.37
SOLY Yearly Current Assets VS Current LiabilitesSOLY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

SOLY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.06%.
EPS 1Y (TTM)-18.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.83% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-61.61%
EPS Next 2Y-6.73%
EPS Next 3Y23.15%
EPS Next 5Y10.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SOLY Yearly Revenue VS EstimatesSOLY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 100M 200M 300M 400M
SOLY Yearly EPS VS EstimatesSOLY Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SOLY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SOLY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SOLY Price Earnings VS Forward Price EarningsSOLY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -19.99
SOLY Per share dataSOLY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

SOLY's earnings are expected to grow with 23.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.73%
EPS Next 3Y23.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SOLY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Soliton Inc

NASDAQ:SOLY (12/15/2021, 8:55:47 PM)

After market: 22.59 +0.01 (+0.04%)

22.58

+0.03 (+0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)12-23 2021-12-23
Earnings (Next)03-03 2022-03-03/amc
Inst Owners0.9%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap485.90M
Analysts47.5
Price Target23.05 (2.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1313.24
P/FCF N/A
P/OCF N/A
P/B 22.74
P/tB N/A
EV/EBITDA -19.99
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.02
BVpS0.99
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.93%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -4832.43%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.47
Quick Ratio 5.37
Altman-Z 63.35
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.12%
EPS Next Y-61.61%
EPS Next 2Y-6.73%
EPS Next 3Y23.15%
EPS Next 5Y10.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A